2025 Q4 -tulosraportti
Vain PDF
50 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 13 791 | - | - | ||
| 35 | - | - | ||
| 1 838 | - | - | ||
| 1 234 | - | - | ||
| 50 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 901 804 | 3 901 804 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 901 804 | 3 901 804 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 30.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·8 t sittenThe strongest are the clinical signals. The report states an 8.5 point improvement on IIEF-EF at week 4 and 7.5 points at week 8 in the relevant patient group, where the company states that ≥5 points are clinically relevant. The effect is thus described not only as statistically interesting but also as clinically meaningful, and furthermore with an unusually long duration for the area. This is probably the single most important positive data point in the report. Another positive signal is the differentiation. The company emphasizes that LIB-01 acts via nervous and vascular structures as well as the melanocortin system, which distinguishes the candidate from current treatments. If this holds in larger studies, it strengthens both commercial positioning and the ability to help patients who do not get sufficient effect from current preparations. The report also mentions potential in other indication areas. The patent aspect is also positive. In November, a new patent application was filed based on the documented long-acting effect, with the explicit purpose of strengthening and extending the intellectual property protection around LIB-01. For a biotech company in this phase, every strengthening of the IP barrier is important, especially when it is linked to clinically observed effect. Another good signal is that the project appears to have moved from “story” to more concrete execution ahead of the next study. The company signed a CRO agreement in December for preparations for phase 2b, and after the end of the fiscal year, it was announced that the tablet formulation had been successfully developed and that manufacturing of active substance and placebo for phase 2b had started. This at least reduces some of the implementation risk ahead of the next value-driving step. There are also signs of increased external interest. Dicot was included in the MSCI Global Micro Cap Index, which according to the report reflects investability based on, among other things, market capitalization, liquidity, and transparency. The company also highlights that Oppenheimer has pointed out LIB-01 as particularly interesting and that Dicot has been invited to several investor presentations, including an invitation-based conference after the turn of the year. It is not the same as a partnership agreement, but it is still a positive signal of increased visibility towards institutional capital. Financially, the picture is mixed but not weak. The clearly positive aspect is that TO 6 was subscribed to 96 percent and contributed 43.8 MSEK before issue costs, and that cash at year-end was 69.2 MSEK and solidity was 85.8 percent. This shows that the company still has a relatively strong balance sheet for its phase.
·31.3.Sold out now?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
50 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sittenThe strongest are the clinical signals. The report states an 8.5 point improvement on IIEF-EF at week 4 and 7.5 points at week 8 in the relevant patient group, where the company states that ≥5 points are clinically relevant. The effect is thus described not only as statistically interesting but also as clinically meaningful, and furthermore with an unusually long duration for the area. This is probably the single most important positive data point in the report. Another positive signal is the differentiation. The company emphasizes that LIB-01 acts via nervous and vascular structures as well as the melanocortin system, which distinguishes the candidate from current treatments. If this holds in larger studies, it strengthens both commercial positioning and the ability to help patients who do not get sufficient effect from current preparations. The report also mentions potential in other indication areas. The patent aspect is also positive. In November, a new patent application was filed based on the documented long-acting effect, with the explicit purpose of strengthening and extending the intellectual property protection around LIB-01. For a biotech company in this phase, every strengthening of the IP barrier is important, especially when it is linked to clinically observed effect. Another good signal is that the project appears to have moved from “story” to more concrete execution ahead of the next study. The company signed a CRO agreement in December for preparations for phase 2b, and after the end of the fiscal year, it was announced that the tablet formulation had been successfully developed and that manufacturing of active substance and placebo for phase 2b had started. This at least reduces some of the implementation risk ahead of the next value-driving step. There are also signs of increased external interest. Dicot was included in the MSCI Global Micro Cap Index, which according to the report reflects investability based on, among other things, market capitalization, liquidity, and transparency. The company also highlights that Oppenheimer has pointed out LIB-01 as particularly interesting and that Dicot has been invited to several investor presentations, including an invitation-based conference after the turn of the year. It is not the same as a partnership agreement, but it is still a positive signal of increased visibility towards institutional capital. Financially, the picture is mixed but not weak. The clearly positive aspect is that TO 6 was subscribed to 96 percent and contributed 43.8 MSEK before issue costs, and that cash at year-end was 69.2 MSEK and solidity was 85.8 percent. This shows that the company still has a relatively strong balance sheet for its phase.
- ·31.3.Sold out now?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 13 791 | - | - | ||
| 35 | - | - | ||
| 1 838 | - | - | ||
| 1 234 | - | - | ||
| 50 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 901 804 | 3 901 804 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 901 804 | 3 901 804 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 30.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
50 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 30.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sittenThe strongest are the clinical signals. The report states an 8.5 point improvement on IIEF-EF at week 4 and 7.5 points at week 8 in the relevant patient group, where the company states that ≥5 points are clinically relevant. The effect is thus described not only as statistically interesting but also as clinically meaningful, and furthermore with an unusually long duration for the area. This is probably the single most important positive data point in the report. Another positive signal is the differentiation. The company emphasizes that LIB-01 acts via nervous and vascular structures as well as the melanocortin system, which distinguishes the candidate from current treatments. If this holds in larger studies, it strengthens both commercial positioning and the ability to help patients who do not get sufficient effect from current preparations. The report also mentions potential in other indication areas. The patent aspect is also positive. In November, a new patent application was filed based on the documented long-acting effect, with the explicit purpose of strengthening and extending the intellectual property protection around LIB-01. For a biotech company in this phase, every strengthening of the IP barrier is important, especially when it is linked to clinically observed effect. Another good signal is that the project appears to have moved from “story” to more concrete execution ahead of the next study. The company signed a CRO agreement in December for preparations for phase 2b, and after the end of the fiscal year, it was announced that the tablet formulation had been successfully developed and that manufacturing of active substance and placebo for phase 2b had started. This at least reduces some of the implementation risk ahead of the next value-driving step. There are also signs of increased external interest. Dicot was included in the MSCI Global Micro Cap Index, which according to the report reflects investability based on, among other things, market capitalization, liquidity, and transparency. The company also highlights that Oppenheimer has pointed out LIB-01 as particularly interesting and that Dicot has been invited to several investor presentations, including an invitation-based conference after the turn of the year. It is not the same as a partnership agreement, but it is still a positive signal of increased visibility towards institutional capital. Financially, the picture is mixed but not weak. The clearly positive aspect is that TO 6 was subscribed to 96 percent and contributed 43.8 MSEK before issue costs, and that cash at year-end was 69.2 MSEK and solidity was 85.8 percent. This shows that the company still has a relatively strong balance sheet for its phase.
- ·31.3.Sold out now?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 13 791 | - | - | ||
| 35 | - | - | ||
| 1 838 | - | - | ||
| 1 234 | - | - | ||
| 50 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 901 804 | 3 901 804 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 901 804 | 3 901 804 | 0 | 0 |